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▪ Clinical pharmacists play an important role in the care of patients 
in hospice/palliative care, particularly for the treatment of pain
▪ One of the core responsibilities of a clinical pharmacist is 
recommending and optimizing individualized medication regimens 
▪ Methadone, a long-active opioid, is particularly useful for pain 
control in many patients in hospice/palliative care, but may be 
underutilized
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▪ The objective of the study was to evaluate the prevalence of 
pharmacist recommendations and subsequent physician 
acceptance for the use of methadone for pain in newly admitted 
hospice/palliative care patients
▪ The study was conducted from October-December 2019 in coordination with a locally-
based pharmacy services organization which works with hospice/palliative care providers 
▪ A selected group of pharmacists at the organization identified new hospice/palliative care 
admissions as part of their usual clinical care process
▪ The first phase of data collected included patient demographics, type of pain, medication 
history, pain intensity and palliative prognosis score (range: 1-100) at the time of 
admission; furthermore, it identified whether a recommendation for methadone was made 
by the pharmacist based on individual indications/contraindications. 
▪ Patients who had recommendations for methadone rendered were followed up with a 
second phase of data collection by a member of the research team
▪ Further data collected included whether the provided recommendation was accepted or 
not, as well as additional patient information including allergies, comorbidities, 
hepatic/renal function, nutritional status pain medication history, current pain intensity 
and palliative prognosis score. 
▪ This research is currently a work-in-progress
▪ Data was analyzed for 158/159 patients based on adult hospice patient inclusion criteria of the study 
▪ The demographic and clinical characteristics of the patients collected through the tool aided the 
pharmacists in making a clinical judgement of providing methadone recommendation or not
▪ The mean sample age of the sample was 79.6 years (SD: 13.8 years) (Table 1)
▪ The mean palliative prognosis score was relatively stable between admission and follow-up (37.2 ±
12.2 vs 37.4 ± 12.1) (Table 1)
▪ Majority type of pain among the patients was nociceptive pain (62; 39.2), missing data on type of 
pain can limit the decision of providing methadone recommendation (Table 2)
▪ Higher utilization of home hospice compared to other hospice types (121; 76.6%) aligns with the 
published literature of this setting (Table 3)
▪ As per the traditional use, the sample population has higher opioids utilization for pain management 
compared to other medication categories (153; 96.8) (Table 4)
▪ Based on the pharmacists’ clinical judgments, 37 (23.4%) methadone recommendations were 
provided; out of which 8 (21.6 %) were accepted by the physicians within the follow-up period
▪ Out of the 8 accepted recommendation, 3 (37.5%) were implemented by the physicians themselves 
▪ The most common recommendation was for maintenance treatment (26; 16.5%) (Table 5)
▪ Majority of the patients were diagnosed with cardiovascular diseases as a comorbidity (116; 73.4%); 
it aligns with the data regarding common contraindication of prescribing methadone being QTc 
prolongation (38; 24.0%)  
▪ The common categories of allergies were antibiotics (46; 23.6%) and opioids (31; 15.6%); opioid 
allergic subpopulation was administered with alternative opioids for pain management 
▪ Clinical outcomes of methadone recommendation accepted patients cannot be extrapolated due to 
missing data in the follow-up period 
Table 1. Demographics 
n Mean (SD)
Height (m) 126 1.6 (0.1)
Weight (kg) 133 65.7 (15.1)
BMI (kg per m
2
) 125 23.8 (5.0)
Age (years) 156 79.6 (13.8)
Palliative prognosis score at admission 150 37.2 (12.1)
Palliative prognosis score at follow-up 146 37.4 (12.0)
Days from date of admission 135 21.2 (24.4)
Table 5. Types of methadone recommendations 
n (%)
Switch to maintenance treatment 26 (16.5)
Addition as adjunctive/adjuvant 7 (4.4)
Other 3 (4.2)
Table 6. Indications for methadone use
n (%)
Neuropathic pain 23 (14.6)
Severe renal impairment 9 (5.7)
Other 6 (3.8)
High opioid tolerance 2 (1.3)
Morphine allergy 3 (1.9)
Refractory to other opioids 2 (1.2)
Conclusion 
▪ Ongoing analysis will continue to assess the data collected to identify patterns in recommendations 
that were provided versus those that were not. 
▪ Further analysis will provide an opportunity to explore methadone interactions with comorbidities as 
a reason for limited acceptance among physicians
Table 2. Type of pain 
n (%)
Nociceptive 62 (39.2)
Neuropathic  5 (3.2)
Both 4 (21.5)
Missing 57 (36.0)








Table 3. Hospice type
n (%)
Home 121 (76.6)
Nursing home 22 (13.9)
Assisted living 10 (6.3)
Inpatient 4 (2.5)
Missing 1 (0.6)
Note: One patient can be included in more than one category
Note: One patient can be included in more than one category
